Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
Doubled survival in metastatic lung cancer with combination therapy

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 3612

Dr Leena Gandhi - NYU Langone Medical Center, New York, USA

Dr Gandhi speaks with ecancer at AACR 2018 about the outcomes of treating non-squamous non-small cell lung cancer with pembrolizumab and chemotherapy.

She discusses the response rates, overall survival and progression-free survival of 616 lung cancer patients whose tumours lacked EGFR or ALK mutations, 405 of whom received the trial combination.

These patients saw their overall risk of death reduced by 51%.

For more on these results, watch Dr Gandhi present the results to the conference in a press session.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation